We thus sought to test if high expression of Drp1(-/17) and the concomitant increase in fused mitochondria may be beneficial to tumor cells when challenged with cisplatin or paclitaxel treatment (Fig. 6A). This evidence concerns the gene DNM1L and neoplasm.